Tali Digital Ltd
TD1.AU
$0.00
Closing
▲33.33%
1D
▲100.00%
YTD
Market cap
$4.26M
52 week high
$0.00
52 week low
$0.00
Volume
516,000
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$4.26M
Analysts' Rating
-
Price Target (Mean)
-
Total Analysts
0
P/E
Operating Margin
-290.94%
Beta
1.09
Revenue Growth (Annual)
-17.77%
52 week high
$0.00
52 week low
$0.00
Div. Yield
%
EPS Annual Growth
0.00
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
TALi Digital Limited is an Australia-based digital health company delivering diagnostic and therapeutic solutions to enhance attention cognitive function. The Company has built a patented platform technology with its first programs targeting cognitive attention skills during early childhood via an evidence-based screening tool (DETECT) and training modules (TRAIN and ReadyAttentionGo!). TALi DETECT assesses three key areas of attention using seven fun and engaging activities that a child plays on a tablet device (iPad/Android devices). After the assessment, it produces a detailed cognitive report outlining performance-based results. TALi TRAIN is a scalable program to train attention skills in early childhood. ReadyAttentionGo! is a digital tool that consists of 25 sessions conducted over a recommended 5-week period. The Company also delivers a series of product developments relevant to Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD).
